These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 33013745)

  • 21. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.
    Agnihothram S; Gopal R; Yount BL; Donaldson EF; Menachery VD; Graham RL; Scobey TD; Gralinski LE; Denison MR; Zambon M; Baric RS
    J Infect Dis; 2014 Apr; 209(7):995-1006. PubMed ID: 24253287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV.
    Fukushi S; Mizutani T; Saijo M; Kurane I; Taguchi F; Tashiro M; Morikawa S
    J Med Virol; 2006 Dec; 78(12):1509-12. PubMed ID: 17063504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout.
    Lee SS; Phy K; Peden K; Sheng-Fowler L
    Vaccine; 2017 Oct; 35(41):5481-5486. PubMed ID: 28427845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays.
    Manu AA; Owusu IA; Oyawoye FO; Languon S; Barikisu IA; Tawiah-Eshun S; Quaye O; Donkor KJ; Paemka L; Amegatcher GA; Denyoh PMD; Oduro-Mensah D; Awandare GA; Quashie PK
    Heliyon; 2024 May; 10(10):e31392. PubMed ID: 38826759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.
    Huang SW; Tai CH; Hsu YM; Cheng D; Hung SJ; Chai KM; Wang YF; Wang JR
    Biomed J; 2020 Aug; 43(4):375-387. PubMed ID: 32611537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays.
    Yu J; Li Z; He X; Gebre MS; Bondzie EA; Wan H; Jacob-Dolan C; Martinez DR; Nkolola JP; Baric RS; Barouch DH
    J Virol; 2021 May; 95(11):. PubMed ID: 33727331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
    Yi CE; Ba L; Zhang L; Ho DD; Chen Z
    J Virol; 2005 Sep; 79(18):11638-46. PubMed ID: 16140741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Lentiviral Pseudotype System to Characterize SARS-CoV-2 Glycoprotein.
    Mi D; Hu J; Qian Z
    Methods Mol Biol; 2023; 2610():187-199. PubMed ID: 36534292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2.
    Hu J; Gao Q; He C; Huang A; Tang N; Wang K
    Genes Dis; 2020 Dec; 7(4):551-557. PubMed ID: 32837985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays.
    Li H; Zhao C; Zhang Y; Yuan F; Zhang Q; Shi X; Zhang L; Qin C; Zheng A
    Emerg Microbes Infect; 2020 Dec; 9(1):2269-2277. PubMed ID: 32990161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
    Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
    J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.
    Alfaleh MA; Alsulaiman RM; Almahboub SA; Nezamuldeen L; Zawawi A; Aljehani ND; Yasir M; Abdulal RH; Alkhaldi R; Helal A; Alamri SS; Malki J; Alhabbab RY; Abujamel TS; Alhakamy NA; Alnami A; Algaissi A; Hassanain M; Hashem AM
    Antib Ther; 2024 Jan; 7(1):53-66. PubMed ID: 38371953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination.
    Zedan HT; Smatti MK; Thomas S; Nasrallah GK; Afifi NM; Hssain AA; Abu Raddad LJ; Coyle PV; Grivel JC; Almaslamani MA; Althani AA; Yassine HM
    JAMA Netw Open; 2023 Jun; 6(6):e2319222. PubMed ID: 37389876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.
    Shen L; Niu J; Wang C; Huang B; Wang W; Zhu N; Deng Y; Wang H; Ye F; Cen S; Tan W
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30918074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting.
    Millet JK; Tang T; Nathan L; Jaimes JA; Hsu HL; Daniel S; Whittaker GR
    J Vis Exp; 2019 Mar; (145):. PubMed ID: 30882796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2.
    Balinsky C; Jani V; Sun P; Williams M; Defang G; Porter KR
    Methods Mol Biol; 2022; 2452():361-378. PubMed ID: 35554917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.
    Jamieson TR; Poutou J; Marius R; He X; Rezaei R; Azad T; Ilkow CS
    J Vis Exp; 2021 Jun; (172):. PubMed ID: 34152313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.